
zzso is a novel zzso that has demonstrated exceptional activity in human zzso models when administered zzso and zzso zzso studies of zzso have shown zzso activity in zzso and zzso zzso This phase I dose escalation study was performed to determine the safety, zzso and zzso profile of orally administered zzso given once every 21 zzso zzso zzso activity of zzso was also zzso 

Key eligibility criteria included adult subjects with zzso solid tumors or solid tumors for which conventional therapy was zzso or did not exist, good performance status zzso ( zzso and adequate zzso zzso and zzso zzso Plasma zzso zzso sampling was performed during the first cycle of zzso 

Five dose levels of zzso ranging from 25 to 75 zzso were evaluated in 18 subjects (four women and 14 zzso zzso was well tolerated at the first three dose levels zzso 37, 50 zzso Two subjects developed zzso zzso zzso at 75 zzso one subject with grade 3 and one subject with grade 4 zzso with zzso Three subjects treated at an intermediate dose level of 60 zzso had no zzso However, the study was terminated prior to completion of the zzso tolerated dose cohort after subjects treated with intravenous zzso in a concurrent study experienced life-threatening zzso Other common zzso included grades 1-2 fatigue and grades 1-2 zzso There was substantial zzso zzso in the zzso zzso zzso was rapidly absorbed with a mean C zzso value of less than 1 zzso Mean C zzso and zzso values generally increased in a zzso zzso The median terminal phase elimination zzso was 45 h zzso zzso zzso Disease stabilization was seen in four subjects with the following zzso zzso zzso zzso zzso (12 zzso small cell zzso (10 zzso and prostate zzso (6 zzso 

zzso can be safely administered orally once every 21 days up to a dose of 60 zzso The major zzso was zzso zzso Four subjects had disease zzso 

